Phase I clinical trial of concurrent paclitaxel, carboplatin, and external beam chest irradiation with glutamine in patients with locally advanced non-small cell lung cancer

Cancer Investigation

Volumn 25, Issue 5, 2007, Pages 294-298

  Jazieh, Abdul Rahman ^a,c   Younas, Ahmer ^a   Safa, Malek ^a   Redmond, Kevin ^b   Buncher, Ralph ^a   Howington, John ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c NONE   (United States)

Author keywords

Carboplatin; Glutamine; Lung cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; GLUTAMINE; PACLITAXEL; SYMPT X; UNCLASSIFIED DRUG;

ADULT; AGED; ANAPHYLAXIS; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CAUCASIAN; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DYSPHAGIA; ESOPHAGITIS; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; HYPERKALEMIA; HYPONATREMIA; HYPOTENSION; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PATIENT SELECTION; RADIOTHERAPY;

EID: 34547502102     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701208758     Document Type: Article

References (30)

1. Jemal, A.; Murray, T.;Ward, E.; Samuels, A.; Tiwari, R.C.; Ghafoor, A.; Feuer, E.J.; Thun, M.J. Cancer statistics. CA Cancer J. Clin. 2005, 55, 10-30.
2. Carney, D.N.; Hansen, H.H. Non-small-cell lung cancer-stalemate or progress? N. Engl. J. Med. 2000, 343, 1261-1262.
3. Choy, H.; Akerley, W.; Safran, H.; Graziano, S.; Chung, C.; et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J. Clin. Oncol. 1998, 16, 3316-3322.
4. Belani, C.P.; Aisner, J.; Bahri, S.; Jett, J.; Day, R.; et al. Chemoradiotherapy in non-small cell lung cancer: paclitaxel/carboplatin/ radiotherapy in regionally advanced disease. Semin. Oncol. 1996, 23, 113-116.
5. Kaplan, B.; Altynbas, M.; Eroglu, C.; Karahacioglu, E.; Er, O.; et al. Preliminary results of a phase II study of weekly paclitaxel PTX) and carboplatin CBDCA) administered concurrently with thoracic radiation therapy TRT) followed by consolidation chemotherapy with PTX/CBDCA for stage III unresectable non-small-cell lung cancer NSCLC, Am. J. Clin. Oncol. 2004, 27, 603-610.
6. Jeremic, B.; Milicic, B.; Acimovic, L.; Milisavljevic, S. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer: long-term results of a phase II study. J. Clin. Oncol. 2005, 23, 1144-1151.
7. Leong, S.S.; Fong, K.W.; Ong, Y.K.; Foo, K.F.; Ang, P.; et al. Chemoradiotherapy for stage III unresectable non-small cell lung cancer long-term results of a prospective study. Respir. Med. 2004, 98, 1080-1086.
8. Choy, H.; LaPorte, K.; Knill-Selby, E.; Mohr, P.; Shyr, Y. Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semin. Radiat. Oncol. 1999, 9, 90-96.
9. Anderson, P.M.; Schroeder, G.; Skubitz, K.M. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer 1998, 83, 1433-1439.
10. Cockerham, M.B.; Weinberger, B.B.; Lerchie, S.B. Oral glutamine for the prevention of oralmucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplantation. Ann. Pharmacother. 2000, 34, 300-303.
11. Jensen, J.C.; Schaefer, R.; Nwokedi, E.; Bevans, D.W.; 3rd, Baker, M.L.; Pappas, A.A.; Westbrook, K.C.; Klimberg, V.S. Prevention of chronic radiation enteropathy by dietary glutamine. Ann. Surg. Oncol. 1994, 1, 157-163.
12. Klimberg, V.S.; Salloum, R.M.; Kasper, M.; Plumley, D.A.; Dolson, D.J.; et al. Oral glutamine accelerates healing of the small intestine and improves outcome after whole abdominal radiation. Arch. Surg. 1990, 125, 1040-1045.
13. Klimberg, V.S.; Souba, W.W.; Dolson, D.J.; Salloum, R.M.; Hautamaki, R.D.; et al. Prophylactic glutamine protects the intestinal mucosa from radiation injury. Cancer 1990, 66, 62-68.
14. Boyle, F.M.; Wheeler, H.R.; Shenfield, G.M. Glutamate ameliorates experimental vincristine neuropathy. J. Pharmacol. Exp. Ther.1996, 279, 410-415.
15. Boyle, F.M.; Wheeler, H.R.; Shenfield, G.M. Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate. J. Neurooncol. 1999, 41, 107-116.
16. Savarese, D.; Boucher, J.; Corey, B. Glutamine treatment of paclitaxel-induced myalgias and arthralgias. J. Clin. Oncol. 1998, 16, 3918-3919.
17. Savarese, D.; Al-Zoubi, A.; Boucher, J. Glutamine for irinotecan diarrhea. J. Clin. Oncol. 2000, 18, 450-451.
18. Ziegler, T.R. Glutamine supplementation in cancer patients receiving bone marrow transplantation and high dose chemotherapy. J. Nutr. 2001, 131, 2578S-2584S; discussion 2590S.
19. Ersin, S.; Tuncyurek, P.; Esassolak, M.; Alkanat, M.; Buke, C.; et al. The prophylactic and therapeutic effects of glutamine- and arginine-enriched diets on radiation-induced enteritis in rats. J. Surg. Res. 2000, 89, 121-125.
20. Belani, C.P.; Barstis, J.; Perry, M.C.; La Rocca, R.V.; Nattam, S.R.; et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J. Clin. Oncol. 2003, 21, 2933-2939.
21. Schaake-Koning, C.; van den Bogaert, W.; Dalesio, O.; Festen, J.; Hoogenhout, J.; et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N. Engl. J. Med. 1992, 326, 524-530.
22. Jeremic, B.; Shibamoto, Y.; Acimovic, L.; Milisavljevic, S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J. Clin. Oncol.1996, 14, 1065-1070.
23. Jeremic, B.; Shibamoto, Y.; Acimovic, L.; Djuric, L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J. Clin. Oncol. 1995, 13, 452-458.
24. Komaki, R.; Lee, J.S.; Milas, L.; Lee, H.K.; Fossella, F.V.; et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58, 1369-1377.
25. Werner-Wasik, M.; Axelrod, R.S.; Friedland, D.P.; Hauck, W.; Rose, L.J.; et al. Preliminary report on reduction of esophagitis by amifostine in patients with non-small-cell lung cancer treated with chemoradiotherapy. Clin. Lung Cancer 2001, 2, 284-289; discussion 290.
26. Antonadou, D.; Pepelassi, M.; Synodinou, M.; Puglisi, M.; Throuvalas, N. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2002, 52, 739-747.
27. Buntzel, J.; Glatzel, M.; Kuttner, K.; Weinaug, R.; Frohlich, D. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Semin. Radiat. Oncol.2002, 12, 4-13.
28. Klimberg, V.S. How glutaime protects the gut during irradiation. ICCN 1996, 3, 21-25.
29. Gandara, D.R.; Chansky, K.; Albain, K.S.; Leigh, B.R.; Gaspar, L.E.; et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J. Clin. Oncol. 2003, 21, 2004-2010.
30. Lau, D.; Leigh, B.; Gandara, D.; Edelman, M.; Morgan, R.; et al. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial. J. Clin. Oncol. 2001, 19, 442-447.